Kornimate/medical-research-clean huggingface dataset:
gastric emptying and insulin response to test drink

Conditions: Insulin Resistance

Summary: surgery is a stress on the body and recovering well after surgery is very important to patients and their doctors. it is therefore important to prepare patient's bodies for the stress of surgery, and one way to do this is to provide proper nutrition. in the past, patients were asked to prepare for surgery by fasting from midnight before surgery. today, it is known that this practice is not beneficial to patient's recovery. in fact, it has been recognized that drinking a sugary beverage (e.g., juice) before surgery stimulates the production of insulin, which is a hormone that helps make the proteins needed for wound healing after surgery. this is currently practiced at the muhc. it might also be beneficial, however, to drink a beverage that contains sugar and whey proteins (a protein isolated from milk) before surgery. in fact, whey proteins stimulate insulin and may also have the added benefit of improving muscular strength. in this study, investigators will measure the level of insulin produced after drinking a carbohydrate (i.e., sugar)-whey protein beverage to determine how it compares to the level of insulin produced after drinking the sugary beverage used at the muhc.

it is hypothesized that the increase in plasma insulin following a mixed carbohydrate whey protein drink is significantly greater than that elicited by a carbohydrate drink.

Eligibility criteria:
inclusion criteria: - healthy volunteer exclusion criteria: * diabetes, * neurological disorders * chronic kidney failure * chronic liver disease * disorders of gastric motility * gastro-esophageal reflux * achalasia * gastroparesis * intestinal obstruction * previous abdominal surgery * lactose intolerance * body mass index below 17 or above 29 * allergy to acetaminophen.
effectiveness of an oxygen-nitrous oxide mixture during physical therapy for frozen shoulder

Conditions: Adhesive Capsulitis

Summary: the purpose of this study is to determine whether or not the use of an equimolar mixture of oxygen and nitrous oxide during the physical therapy for patients suffering from frozen shoulder (adhesive shoulder capsulitis) results in a gain in shoulder amplitude (constant score) and less pain as compared to patients undergoing physical therapy without this treatment.


Eligibility criteria:
inclusion criteria: * affiliated with a social security system * has signed the consent form * patient has a painful, or initially painful but stable frozen shoulder (adhesive capsulitis): stiffening characterized by a passive loss of amplitude on three planes. this loss of amplitude is greater than or equal to 50% of controlateral amplitude when the controlateral shoulder is considered as normal. otherwise, the loss of amplitude is greater than or equal to 50% of normal anatomical values. * radiography confirms the integrity of the glenohumeral interspace. exclusion criteria: * intercurrent, evolving or unstable pathology: cancer, advanced cardio-vascular pathology, severe infection * the patient is taking a treatment that may interfere with the study (eg corticoids, pain killers, chemotherapy) * contra-indication for physical therapy * coagulopathy * advanced diabetes mellitus, with neurological or joint complications * contra indication for the experimental treatment * pregnant or nursing women * patient's mental state prevents him/her from understanding the nature of the study, its objectives and potential consequences. * patient under guardianship * patient is in an exclusion period determined by a previous study * patient not able to follow protocol constraints or timetable * medical history of local infection, polyarthritis or neuropathy that might explain the shoulder pain. * absence of radiculopathy of cervical origin, of rotator cuff tears or evolving shoulder tendinopathy, of severe omarthrose
efficacy of balance training in patients with rotator cuff disease

Conditions: Rotator Cuff Injury

Summary: the purpose of the study is to determine whether balance training is effective in patients with rotator cuff disease.


Eligibility criteria:
inclusion criteria: * verification of the diagnosis of rotator cuff disease by a medical practitioner via radiological techniques. * pain due to unilateral rotator cuff disease at least four weeks. exclusion criteria: * systemic pathology including inflammatory joint disease. * more than %50 restriction of passive range of motion in two or more planes. * history of major surgery on the lower extremities and shoulder regions. * acute or chronic pain in the spine or lower extremities. * an injury of the lower extremities during the last six months which affected functional capabilities. * any kind of neurological complaint. * cardiovascular diseases which affect balance. * acute dizziness * medications which affected balance * subjects who performed balance training
a study to assess the relative bioavailability of a modified-release formulation of pf-05180999

Conditions: Healthy

Summary: the purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of pf-05180999 relative to an immediate-release formulation in healthy adult subjects. two doses of the modified-release formulation and one dose of the immediate-release formulation will be evaluated under fasted conditions. one dose of the modified-release formulation will also be evaluated in the presence of food.


Eligibility criteria:
inclusion criteria: * male or female of non-childbearing potential exclusion criteria: * evidence of clinically-significant medical illness, history of seizures, any condition possibly affecting drug absorption

Keywords: pf-05180999 safety pharmacokinetics relative bioavailability mental disorders schizophrenia and disorders with psychotic features schizophrenia
comparing evco and evoo

Conditions: Obesity; Appetitive Behavior

Summary: the aim of this study is to compare acute effects of consuming extra virgin coconut oil (evco) as a source of medium chain fatty acids and extra virgin olive oil (evoo) as a source of long chain fatty acids in normal weight and obese subjects.

twenty male subjects (10 normal weight; 10 obese) consumed breakfast meals containing skimmed milk, fat-free white cheese, bread and evco (25 g) or evoo (25 g). visual analog scale evaluations, resting metabolic rate measurements and selected blood parameters analysis (glucose, triglyceride, insulin and plasma peptide yy) were performed before and after the test breakfast meals. in addition, energy intakes were evaluated by ad libitum lunch meal at 180 min.

Eligibility criteria:
inclusion criteria: * metabolically healthy * aged 19-40 years * normal weight (bmi=18.5-24.9 kg/m²) and obese men (bmi=30-34.99 kg/m²) exclusion criteria: * smoking, * alcohol consumption, * weight gain/loss recently (\> %5, in three months), * any genetic and metabolic diseases, * any food allergy/intolerance, * any medication, * restrained eating habits.

Keywords: extra virgin coconut oil; medium chain fatty acids; extra virgin olive oil; obesity; peptide yy; resting metabolic rate.
sbrt combined with zimberelimab (gls-010) in locally advanced pancreatic cancer (spark-1 study)

Conditions: Locally Advanced Pancreatic Cancer

Summary: this trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by sbrt combined with zimberelimab(gls-010).

this a prospective, single-arm, multicenter study evaluating the efficacy and safety of stereotactic radiotherapy (sbrt) and zimberelimab(gls-010) in patients with pancreatic cancer. the primary endpoint is os, and the secondary are pfs, orr,dcr and adverse events.

Eligibility criteria:
inclusion criteria: * 18-75 years old. * locally advanced pancreatic cancer confirmed histologically and defined according to the nccn pancreatic cancer guidelines v1.2022 as unresectable or surgically declined. * eastern cooperative oncology group (ecog) performance status 0-2. * the expected survival ≥ 3 months. * at least one tumor lesion meeting measurable disease criteria as determined by recist v1.1. * patient must have adequate organ function defined by the study-specified laboratory tests. exclusion criteria: * tumor invasion of the gastrointestinal tract, specifically pancreatic tumor or lymph node metastasis invading the gastrointestinal parenchyma. * woman who are pregnant or breastfeeding. * has a known additional malignancy within the past 5 years, except for cured skin cancer and cervical carcinoma in situ. * patients who have received prior treatment with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-ctla-4, or with an agent directed to another stimulatory or co-inhibitory t-cell receptor. * contraindications to immunotherapy. * other conditions that investigator decides not suitable for the trial.

Keywords: locally advanced pancreatic cancer sbrt zimberelimab
a study in children and young people with migraine to learn what the body does to eptinezumab

Conditions: Migraine in Children; Migraine

Summary: the purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.

this is an interventional, open-label pharmacokinetic study with eptinezumab, consisting of a single-dose, 20-week main study period (part a) and an optional 44-week multiple-dose extension period (part b). the main study period includes a single iv infusion of eptinezumab. the optional extension period includes 3 additional eptinezumab infusions 12 weeks apart (reflecting recommended dosing interval in adults), for a total of up to 4 infusions over the course of the study. at least 32 patients with migraine will be enrolled: 16 patients aged 6 to 11 years, and 16 patients aged 12 to 17 years, inclusive.

Eligibility criteria:
inclusion criteria: * the patient has a diagnosis of migraine with or without aura according to international classification of headache disorders (ichd)-3 (in the opinion of the investigator) for ≥6 months prior to the screening visit and has a frequency of migraine ≥4 migraine days per month for at least 3 months prior to the screening visit. exclusion criteria: * the patient has been exposed to any monoclonal antibody treatment (including exposure in a study) \<6 months prior to the screening visit. other in- and exclusion criteria may apply
a reduced 11-b-hsd activity, a novel mechanism of salt sensitivity and hypertension after renal allograft donation?

Conditions: Renal Failure; Renal Transplantation; Living Donors

Summary: consecutive living-kidney donor candidates (n=100) will be recruited after being accepted for donation according to official guidelines. an assessment of salt sensitivity, 11 beta hsd activity, 24 hour blood pressure, urine collection and physical exam will be performed prior nephrectomy and 14, 52, 156, 208 days post-nephrectomy.

consecutive living-kidney donor candidates (n=100) will be recruited after being accepted for donation. the assessment of salt sensitivity, 11 beta hsd activity, 24 hour blood pressure, urine collection and physical exam will be performed prior nephrectomy and 14, 52, 156, 208 days post-nephrectomy.

Eligibility criteria:
inclusion criteria: * acceptance for living kidney donation exclusion criteria: * withdrawal of consent
sugar-replacement sweeteners, and blood sugar control

Conditions: Obesity

Summary: several sugar-replacement sweeteners are currently on the market, including saccharine (ex. sweet'n low), aspartame (ex. equal), and sucralose (ex. splenda). the purpose of this study is to examine wether non caloric sweeteners affects how well the body works to control blood sugar. the study includes detailed blood sugar testing after drinking liquids that may contain sucralose. the investigators hypothesize that drinking liquids with sucralose will effect the amounts of specific appetite-affecting substances naturally produced by the body.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) over 30. * homeostasis model assessment of insulin resistance (homa-ir) \< or = 2.6 exclusion criteria: * smoking or smoked within last six months * pregnant or breastfeeding * have malabsorptive syndromes * intestinal inflammatory disease * diabetes * liver or kidney disease * fructose intolerance * consuming more than one can of diet beverage or one spoonful of non-nutritive sweeteners (e.g. sucralose, aspartame, or saccharine) a week. * taking any medication that might affect metabolism or taste.

Keywords: obesity diabetes artificial sweeteners
assessment of the decision-making impact of the breast cancer index in recommending extended adjuvant endocrine therapy for patients with early stage er-positive breast cancer

Conditions: Breast Cancer; Early Stage Estrogen Receptor (ER) Positive Breast Cancer

Summary: investigators will examine the impact of the breast cancer index (bci) result on patients' anxiety / fear of recurrence and satisfaction with decisions regarding endocrine therapy.

the investigators' objective is to assess patient decision-making, anxiety and patient satisfaction with recommendations made by an oncologist before and after the bci test results are known. in addition, a chart review will be performed annually for five years to assess disease status and medications. specifically, if extended endocrine therapy was recommended the chart review will record if participants are taking the medication and, if not, why the treatment was discontinued.

Eligibility criteria:
inclusion criteria: each patient must meet all of the following criteria in order to be considered for enrollment: * histologically confirmed er positive, stage i-iii breast cancer who have been treated with curative intent and completed at least four years of adjuvant endocrine therapy. * life expectancy ≥ 5 years. * must be able to provide informed consent. * willing to consider continuation of endocrine therapy beyond 5 years. exclusion criteria: * a patient must not be enrolled if any contraindication exists for extended adjuvant endocrine therapy as identified by the treating oncologist.

Keywords: estrogen receptor (er) positive early stage breast cancer breast cancer index
oral care study of postoperative infections

Conditions: Cancer, Mouth

Summary: reduce the incidence of post-operative infections after ent surgery and flap reconstruction by performing preoperative oral and dental care

reduce the incidence of post-operative infections after ent surgery and flap reconstruction by performing preoperative oral and dental care

Eligibility criteria:
inclusion criteria: * ent surgery with free flap reconstruction exclusion criteria: * allergy to chlorhexidine
study in chronic kidney disease (ckd) not on dialysis

Conditions: Hyperphosphatemia

Summary: the objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in japanese chronic kidney disease stage 3, 4 and 5 subjects not on dialysis.


Eligibility criteria:
inclusion criteria: * male and female patients aged 20 years or above at the time of informed consent * chronic kidney disease patients with epidermal growth factor receptor (egfr) under 60 ml/min/1.73m2 (stage 3, 4 and 5) who have not been on dialysis * patients who had been in the care of a physician for chronic kidney disease for \>2 months and was not expected to begin dialysis for at least 4 months * patients with serum phosphate levels 5.6 mg/dl to 11.0 mg/dl at week -4 (visit 1) or week -2 (visit 2) exclusion criteria: * patients with hypocalcemia or hypercalcemia (corrected serum calcium level of \ /- 11.0 mg/dl) at week -2 (visit 2). * significant renal impairments * had acute renal failure within 3 months of run-in period

Keywords: chronic kidney disease not on dialysis lanthanum carbonate
r3® acetabular system in patients with degenerative hip disease

Conditions: Osteoarthritis

Summary: this is a prospective, non-randomized, consecutive series, multicenter clinical study that will include patients who will have total hip replacement with the r3 acetabular system.

the study design was selected to assess the safety and effectiveness profile of the r3 acetabular system in patients with degenerative joint disease requiring primary total hip replacement. a non¬-randomized, consecutive series of up to 158 patients will be enrolled, and a maximum of 8 sites will participate in the study. each site is allowed to enroll up to 22 patients. when 158 patients are enrolled from all sites, enrollment will be stopped, regardless of the number contributed from each site. the clinical data from this study will be compared with a historical control. the study will include follow up through 5 years.

Eligibility criteria:
inclusion criteria: * patient is of legal age to consent and skeletally mature. * patient requires primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, avascular necrosis, and dysplasia/ddh) * patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk. * the patient will be available for follow-up throughout the duration of the study. exclusion criteria: * patient has active infection or sepsis (treated or untreated) * patient has any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery. * patient is pregnant or plans to become pregnant during the course of the study patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia) * patient has inflammatory joint disease (e.g. rheumatoid arthritis) * patient has known moderate to severe renal insufficiency. * patient has a known or suspected metal sensitivity. * patient is immunosuppressed or receiving high doses of corticosteroids. * patient has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, or drug, alcohol abuse. * patient has bmi \>40. * patient is a prisoner
content validation of quality of life and symptom questionnaires for pheochromocytoma and paraganglioma

Conditions: Pheochromocytoma; Paraganglioma

Summary: the purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.


Eligibility criteria:
inclusion criteria: * provide written informed consent and be willing to comply with protocol requirements * participant is aged ≥ 18 * have a documented (medical record) diagnosis of either pheochromocytoma or paraganglioma with active symptoms or within 60 days of curative therapy exclusion criteria: patient is currently asymptomatic from pheochromocytoma/paraganglioma diagnosis or duration \> 60 days from curative therapy * participant has a clinically significant disorder, including alcohol or drug abuse, which may interfere with study participation or which may affect the outcome of the study as judged by the investigator. * participant has a mental disability or significant mental illness, legal incapacity or limited legal capacity or any other lack of fitness, in the investigator's opinion, to preclude the subject's participation in or ability to complete the study. * participant is currently too unwell to take part in the study.

Keywords: paraganglioma pheochromocytoma
evaluation of the 4th generation quantiferon-tb test (qft-plus) for the detection of tuberculosis infection

Conditions: Tuberculosis

Summary: to compare the positivity rate of the investigational assay to the currently approved quantiferon-tb gold in-tube assay.


Eligibility criteria:
low risk and known risk cohorts inclusion criteria: * compensated and uncompensated members (current or future) of the department of veterans affairs with no identified symptoms of active tb disease * age greater than 18 years or less than 80 years. exclusion criteria: * currently taking therapy for active tuberculosis or latent tb infection for more than 14 days.

Keywords: tuberculosis tb
peripherally inserted versus centrally inserted central venous catheters in the neurological intensive care

Conditions: Venous Thrombosis

Summary: the investigators aim to compare the complications between centrally and peripherally inserted central venous catheters in neurological intensive care unit patients. the study hypothesis is that peripherally inserted catheters will have more cumulative complications due to venous thrombosis.


Eligibility criteria:
inclusion criteria: * all patients age \> 18, admitted to the neurological icu who are require a de novo central venous catheter as standard of care and in which a double lumen 5f picc or cicvc (triple lumen, 7f) are acceptable for the indication. * the patients must be expected to survive and need a central venous catheter for at least 7 days. exclusion criteria: * prisoner * age \< 18 * expected to die or have care withdrawn prior to icu day 7 * requiring an emergent central venous catheter * suspected bacteremia * recent central venous catheter within the last 30 days * patients who are not a candidate for bedside placement of either a cicvc or picc line * patients with renal insufficiency with creatinine level greater than 3.0 mg/dl (265.2 m mol/l) or who were undergoing hemodialysis * patients requiring a central venous catheter for prolonged antibiotic therapy\\ * patient who the treating clinician feels clearly needs one particular type of catheter over the other

Keywords: catheter related large vein thrombosis upper extremity deep venous thrombosis central venous catheters upper extremity catheter related large vein thrombosis
a study comparing two standard of care adjuvant chemotherapy regimens for lower risk her-2 positive breast cancer

Conditions: Breast Neoplasms

Summary: multi-center, open-label, randomized trial of patients with low-risk, her2+ disease, who will receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with trastuzumab \[tc-h\] or weekly paclitaxel with trastuzumab \[p-h\]) at the standard approved doses, aiming to gather more information regarding cost-effectiveness, toxicity, quality of life (qol), patient reported outcomes and clinical benefits of the two treatment strategies.

multi-center, open-label, randomized trial of patients with low-risk, her2+ disease, who will receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with trastuzumab \[tc-h\] or weekly paclitaxel with trastuzumab \[p-h\]) at the standard approved doses. the primary objective is to estimate the feasibility of opening a pragmatic clinical trial with an integrated consent model secondary objectives are: compare adverse events/ toxicity profile between the two different approaches (i.e. neutropenia, peripheral neuropathy, treatment-related hospitalizations, proportion of patients completing the chemotherapy component of their treatment); estimate the cost of each chemotherapy regimen and potential cost-effectiveness analysis from the perspective of canada's health care system; evaluate the impact on activities of daily living as reflected by self-reported fatigue and pain using the fact-taxane and facit-fatigue scores. in this study, the investigator will obtain oral consent using the prepared reb approved consent script. if the patient agrees to participate, the physician will dictate in the progress note they have had the above conversation with the patient. there will be no need for the patient to sign an informed consent form.

Eligibility criteria:
inclusion criteria: * patients with her-2 positive early stage breast cancer for whom tc-h or weekly p-h is being considered. * able to provide verbal consent. * willing to complete study related-questionnaires exclusion criteria: * unable to give informed consent or complete questionnaires